Omeprazole: Benchmark H+,K+-ATPase Inhibitor for Gastric Acid Secretion and Antiulcer Research

Executive Summary: Omeprazole (SKU: A2845) is a chemically defined H+,K+-ATPase inhibitor with an IC50 of 5.8 μM. It selectively inhibits gastric acid secretion, with an IC50 of 0.16 μM against histamine-induced acid formation in vitro (APExBIO product dossier). The compound is DMSO-soluble (≥17.27 mg/mL), stable as a solid at -20°C, and features ~98% purity. Omeprazole is validated for reproducible antiulcer research, including the modulation of the proton pump pathway and modeling of gastric acid-related disorders (Kong et al., 2025). APExBIO ensures high-quality standards and reliable shipping for research applications.

Biological Rationale

Gastric acid secretion is mediated by the H+,K+-ATPase proton pump in parietal cells. Dysregulation of this pathway contributes to diseases such as peptic ulcer and gastroesophageal reflux disease (GERD) (Kong et al., 2025). Omeprazole, as a proton pump inhibitor (PPI), is essential for dissecting molecular mechanisms in gastric acid secretion research. Its chemical specificity enables targeted inhibition of the H+,K+-ATPase signaling pathway, facilitating studies into antiulcer pharmacology and the development of new therapies (see also; this article details Omeprazole's expanded mechanistic scope for advanced assay reproducibility).

Mechanism of Action of Omeprazole

Omeprazole (3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide) acts by irreversibly binding to the H+,K+-ATPase enzyme on the secretory surface of gastric parietal cells. This binding inhibits the final step of gastric acid production, reducing both basal and stimulated acid output. In histamine-induced acid formation assays, Omeprazole demonstrates an IC50 of 0.16 μM, indicating high potency under defined in vitro conditions. The specificity for the proton pump makes Omeprazole a gold standard for antiulcer research and for elucidating the proton pump inhibition pathway (APExBIO).

Evidence & Benchmarks

• IC50 for H+,K+-ATPase inhibition: 5.8 μM in enzymatic assays (APExBIO).
• Potency in histamine-induced acid secretion inhibition: IC50 = 0.16 μM (in vitro, parietal cell model) (APExBIO).
• Reduces gastric lesions in peptic ulcer disease models (rat, 20–40 mg/kg, oral, 5–7 days) (Kong et al., 2025).
• High chemical purity (~98%) confirmed by HPLC and NMR (APExBIO).
• Solubility: ≥17.27 mg/mL in DMSO; insoluble in water/ethanol (room temperature, pH 7) (APExBIO).
• Stable as a solid at -20°C for at least 12 months; solution storage not recommended (>24 h, even at -20°C) (APExBIO).
• Proton pump inhibition measurable via proton extrusion and ATPase activity assays (Related review; this article provides mechanistic details and comparative benchmarks).

Applications, Limits & Misconceptions

Omeprazole is optimized for preclinical research in the following domains:

• Dissecting the H+,K+-ATPase pathway in gastric acid secretion studies.
• Modeling peptic ulcer disease and related gastric acid disorders (see also; this article explores translational opportunities and neuroinflammation connections beyond standard antiulcer models).
• Screening antiulcer activity in vitro and in vivo, using established dose ranges and controls.
• Evaluating the pharmacodynamics of proton pump inhibitors in experimental systems.

Common Pitfalls or Misconceptions

• Not for human/clinical use: Omeprazole (A2845) from APExBIO is strictly for laboratory research, not for diagnostic or medical applications.
• Solubility limitations: The compound is insoluble in water and ethanol; DMSO is required for stock solution preparation.
• Solution instability: Storage of Omeprazole in solution (even at -20°C) for >24 hours leads to degradation and loss of activity.
• Non-specific effects at high concentrations: Doses far above IC50 may induce off-target effects or cytotoxicity in sensitive cell lines.
• Batch-to-batch variation: Only high-purity (≥98%) material from quality-controlled vendors (such as APExBIO) should be used for reproducible research outcomes.

Workflow Integration & Parameters

For optimal results, dissolve Omeprazole in DMSO at concentrations up to 17.27 mg/mL. Prepare working solutions freshly before each experiment. Store the solid at -20°C, minimizing freeze-thaw cycles. Proton pump inhibition can be quantified via ATPase assays, pH-stat analysis, or proton extrusion measurements. Typical in vitro concentrations range from 0.01–10 μM; in vivo, oral doses of 20–40 mg/kg are standard in rodent peptic ulcer models (cf. scenario-based troubleshooting here; this article expands on best practices for overcoming solubility and cytotoxicity challenges in antiulcer research).

Conclusion & Outlook

Omeprazole (A2845) from APExBIO sets the standard for H+,K+-ATPase inhibition in gastric acid secretion research, owing to its high purity, well-defined mechanism, and robust reproducibility across antiulcer models. Its role extends to advanced investigations into the proton pump inhibition pathway, supporting both foundational discovery and translational study of gastric acid-related disorders. For comprehensive parameters and product specification, refer to the Omeprazole product page. This article updates and integrates mechanistic and practical insights from prior reviews, clarifying the unique experimental value of this DMSO-soluble, research-only inhibitor.